Journal Mobile Options
Table of Contents
Vol. 73, No. 1, 2001
Issue release date: January 2001

In vivo and in vitro Effects of Ghrelin/Motilin-Related Peptide on Growth Hormone Secretion in the Rat

Tolle V. · Zizzari P. · Tomasetto C. · Rio M.-C. · Epelbaum J. · Bluet-Pajot M.-T.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Ghrelin (Ghr), a 28 amino acid gastric peptide with an n-octanoylation on Ser 3, has recently been identified as an endogenous ligand of the growth hormone secretagogue (GHS) receptor. A cDNA was also isolated from a mouse stomach library encoding a protein named prepromotilin-related peptide (ppMTLRP) which shares sequence similarities with prepromotilin. Mouse and rat ppMTLRP sequences (rGhr) are identical and show 89% identity with human ghrelin (hGhr). By analogy with promotilin, cleavage of proMTLRP into an 18 amino acid endogenous processed peptide can be assumed on the basis of a conserved dibasic motif in position 9–10 of its sequence. In the present work, we compared the GH-releasing activity of rGhr28/MTLRP and of hGhr28/MTRLP with that of a shorter form of the peptide, hGhr18. A short peptide devoid of Ser-3 n-octanoylation hGhr18[–] was also tested. Addition of rGhr28, hGhr28 and hGhr18 stimulated GH release to the same extent from superfused pituitaries. The effect was dose dependent in a 10–8 to 10–6M concentration range. In contrast, hGhr 18[–] was inactive. In freely moving animals, both rGhr28 and hGhr28 (10 µg, i.v.) stimulated GH release, whereas the same dose of hGhr18 or of hGhr18[–] was ineffective. After rGhr28, GH plasma levels increased as early as 5 min after injection and returned to basal values within 40–60 min. Expressed as percent stimulation, administration of rGhr28 was equally effective when injected during troughs or peaks of GH. Plasma concentrations of prolactin, adrenocorticotropin and leptin were not modified. Spontaneous GH secretory episodes were no longer observed within 3 h of rGhr28 treatment, but repeated administration of the secretagogue at 3- to 4-hour intervals resulted in a similar GH response. Activation of somatostatin (SRIH) release by ether stress did not blunt the GH response to rGhr28. This suggests that the secretagogue acts in part by inhibiting endogenous SRIH, as further substantiated by the ability of rGhr28 (10–6M), to decrease the amplitude of 25 mM K+-induced SRIH release from perifused hypothalami. In conclusion, (1) n-octanoylation of Ghrs and the shorter form hGhr18 is essential for the direct pituitary GH-releasing effect of this new family of endogenous GHSs; (2) only the longer forms are active in vivo and (3) inhibition of SRIH release appears involved in the mechanism of Ghr action.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Smith RG, Van der Ploeg LH, Howard AD, Feighner SD, Cheng K, Hickey GJ, Wyvratt MJ Jr, Fisher MH, Nargund RP, Patchett AA: Peptidomimetic regulation of growth hormone secretion. Endocr Rev 1997;18:621–645.
  2. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nargund R, Griffin PR, De Martino JA, Gupta SK, Schaeffer JM, Smith RG, Van Der Ploeg LHT: A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996;273:974–977.
  3. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kangawa K: Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999;402:656–660.
  4. Tomasetto C, Karam SM, Ribieras S, Masson R, Lefebvre O, Staub A, Alexander G, Chenard MP, Rio MC: Identification and characterization of a novel gastric peptide hormone: The motilin-related peptide. Gastroenterology 2000;119:395–405.
  5. Ghigo E, Arvat E, Muccioli G, Camanni F: Growth hormone-releasing peptides. Eur J Endocrinol 1997;136:445–460.
  6. Tschöp M, Smiley DL, Heiman ML: Ghrelin induces adiposity in rodents. Nature 2000;407:908–913.
  7. Bluet-Pajot MT, Durand D, Drouva SV, Mounier F, Pressac M, Kordon C: Further evidence that thyrotropin-releasing hormone participates in the regulation of growth hormone secretion in the rat. Neuroendocrinology 1986;44:70–75.
  8. Ezan E, Laplante E, Bluet-Pajot MT, Mounier F, Mamas S, Grouselle D, Grognet JM, Kordon C: An enzyme immunoassay for rat growth hormone: Validation and application to the determination of plasma levels and in vitro release. J Immunoassay 1997;18:335–356.

    External Resources

  9. Duhau L, Grassi J, Grouselle D, Enjalbert A, Grognet JM: An enzyme immunoassay for rat prolactin: Application to the determination of plasma levels. J Immunoassay 1991;12:233–250.
  10. Rorstad OP, Epelbaum J, Brazeau P, Martin JB: Chromatographic and biological properties of immunoreactive somatostatin in hypothalamic and extrahypothalamic brain regions of the rat. Endocrinology 1979;105:1083–1092.

    External Resources

  11. Veldhuis JD, Carlson ML, Johnson ML: The pituitary gland secretes in bursts: Appraising the nature of glandular secretory impulses by simultaneous multiple-parameter deconvolution of plasma hormone concentrations. Proc Natl Acad Sci USA 1987;84:7686–7690.
  12. Fairhall KM, Mynett A, Smith RG, Robinson ICAF: Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585. J Endocrinol 1995;145:417–426.
  13. Dickson SL, Doutrelant-Viltart O, Dyball RE, Leng G: Retrogradely labelled neurosecretory neurones of the rat hypothalamic arcuate nucleus express Fos protein following systemic injection of GH-releasing peptide-6. J Endocrinol 1996;151:323–331.
  14. Ong H, McNicoll N, Escher E, Collu R, Deghenghi R, Locatelli V, Ghigo E, Muccioli G, Boghen M, Nilsson M: Identification of a pituitary growth hormone-releasing peptide (GHRP) receptor subtype by photoaffinity labeling. Endocrinology 1998;139:432–435.
  15. Feighner SD, Tan CP, McKee KK, Palyha OC, Hreniuk DL, Pong SS, Austin CP, Figueroa D, MacNeil D, Cascieri MA, Nargund R, Bakshi R, Abramovitz M, Stocco R, Kargman S, O’Neill G, Van Der Ploeg LH, Evans J, Patchett AA, Smith RG, Howard AD: Receptor for motilin identified in the human gastroinestinal system. Science 1999;284:2184–2188.
  16. Miller P, Gagnon D, Dickner M, Aubin P, St-Pierre S, Poitras P: Structure-function studies of motilin analogues. Peptides 1995;16:11–18.
  17. Raymond MC, Boivin M, St-Pierre S, Gagnon D, Poitras P: Studies on the structure-activity of motilin in vivo. Effect of motilin synthetic analogues in conscious dog. Regul Pept 1994;50:121–126.
  18. Tannenbaum GS, Ling N: The interrelationships of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion. Endocrinology 1984;115:1952–1957.
  19. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO: Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990;70:975–982.
  20. Cordido F, Penalva A, Dieguez C, Casanueva FF: Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity (see comments). J Clin Endocrinol Metab 1993;76:819–823.
  21. Tannenbaum GS, Lapointe M, Beaudet A, Howard AD: Expression of growth hormone secretagogue-receptors by growth hormone-releasing hormone neurons in the mediobasal hypothalamus. Endocrinology 1998;139:4420–4423.
  22. Willesen MG, Kristensen P, Romer J: Co-localization of growth hormone secretagogue receptor and NPY mRNA in the arcuate nucleus of the rat. Neuroendocrinology 1999;70:306–316.
  23. Bowers CY, Sartor AO, Reynolds GA, Badger TM: On the actions of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991;128:2027–2035.
  24. Conley LK, Teik JA, Deghenghi R, Imbimbo BP, Giustina A, Locatelli V, Wehrenberg WB: Mechanism of action of hexarelin and GHRP-6: Analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology 1995;61:44–50.
  25. Korbonits M, Little JA, Forsling ML, Tringali G, Costa A, Navarra P, Trainer PJ, Grossman AB: The effect of growth hormone secretagogues and neuropeptide Y on hypothalamic hormone release from acute rat hypothalamic explants. J Neuroendocrinol 1999;11:521–528.
  26. Lanzi R, Tannenbaum GS: Time course and mechanism of growth hormone’s negative feedback effect on its own spontaneous release. Endocrinology 1992;130:780–788.
  27. Pellegrini E, Bluet-Pajot MT, Mounier F, Bennett P, Kordon C, Epelbaum J: Central administration of a growth hormone (GH) receptor mRNA antisense increases GH pulsatility and decreases hypothalamic somatostatin expression in rats. J Neurosci 1996;16:8140–8148.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50